Safety and how the body handles HMB-003 in healthy adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 interventional study will enroll healthy adults aged 18 to 50 to receive HMB-003 or placebo. Researchers will monitor tolerability, side effects, and collect pharmacokinetic data to understand how the drug is absorbed, distributed, metabolized, and eliminated. The trial will help determine initial safety signals and dosing considerations for future studies. Participation requires medical screening, adherence to the protocol, and avoidance of other investigational products during the study window. The lead sponsor is Hemab ApS, with sites at Worldwide Clinical Trials in San Antonio, TX, and no listed collaborators.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant is aged 18 to 50 years, inclusive, at the time of signing informed consent.
* Overall healthy as determined by medical evaluation including physical examination, vital signs, laboratory tests, and ECG.

Exclusion Criteria:

* Participant has a history of clinically significant hypersensitivity to any excipients of the study drug
* Participant is pregnant, breastfeeding, or \<6 weeks postpartum.
* Participant has received investigational drug or device in another clinical study within 30 days or 5 half-lives, whichever is longer, before dosing.

Where it's running

• Worldwide Clinical Trials
  San Antonio, Texas, United States Recruiting

Study contacts

• Study coordinator: Clinical Trials
• Email: clinicaltrials@hemab.com
• Phone: 001 888 493 8148

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How age affects germinal center responses after flu and rabies vaccines

  Researchers will test how the immune system responds to flu and rabies vaccines in younger adults (18–40) and older adults (65+).

  Recruiting Phase 4 Washington University School of Medicine · St Louis, Missouri · NCT07914673

• Magnetic field maps with NV sensors for non-invasive heart measurements

  This study tests whether diamond-based NV magnetometers can non-invasively detect and map the heart's magnetic field in healthy adults.

  Recruiting Robert Bosch GmbH · Renningen · NCT07908173

• Methylation analyses using home-based self-sampling in women with and without gynecological disease

  This study tests whether self-collected urine and vaginal samples can reveal DNA methylation markers that distinguish people with gynecological (pre-)cancers from cancer-free controls.

  Recruiting Universiteit Antwerpen · Edegem, Antwerp · NCT07902388

• Omega-3 status in healthy adults: comparing different fish-oil and algae-oil products

  This study tests whether various fish-oil and algae-oil products can raise the Omega-3 Index in healthy adults who don’t eat much fatty fish.

  Recruiting Nordic Naturals · London, Ontario · NCT07900425

• A safe, carefully dosed test of TBD11 in healthy adults

  This phase 1 study tests TBD11 in healthy adults to see if it is safe and tolerable and to understand how it behaves in the body, including how it interacts with other medicines.

  Recruiting Phase 1 Gates Medical Research Institute · Bloemfontein · NCT07883226

• Fosmanogepix in healthy adults: how it may interact with other drugs and heart rhythm

  This study tests whether fosmanogepix (and its active form manogepix) changes how other medicines work in healthy adults.

  Recruiting Phase 1 Basilea Pharmaceutica · Groningen, Netherlands · NCT07881224

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.